Skip to main content
Livermore
Livermore
ZHEN

Great Point Partners LLC

SEC CIK
0001281446
Latest filing
Aug 14, 2026

Holdings in Q3 2021

Holdings as of Sep 30, 2021, filed Nov 15, 2021. Long positions only; changes compare share counts with Q2 2021.

Institution overview
Positions
35
+7 vs. Q2 2021
Portfolio value
$422.9M
−$24.3M (−5.4%) vs. Q2 2021
Filed
Nov 15, 2021
SEC
Holdings of Great Point Partners LLC in Q3 2021
SecurityClassSharesValue% of portfolioShare changeActionHistory
EXELExelixis, Inc.COM1,525,000$32.2M7.6%+130,893+9.4%AddedHistory
ARNAArena Pharmaceuticals IncCOM NEW530,670$31.6M7.5%+25,000+4.9%AddedHistory
KDMNKadmon Holdings, Inc.COM3,375,000$29.4M7.0%−1,455,000−30.1%ReducedHistory
BCABBioAtla, Inc.COM844,002$24.8M5.9%+844,002NewHistory
RCKTRocket Pharmaceuticals, Inc.COM765,000$22.9M5.4%−52,040−6.4%ReducedHistory
MGNXMacrogenics IncCOM1,000,000$20.9M5.0%−378,495−27.5%ReducedHistory
DRNADicerna Pharmaceuticals IncCOM799,999$16.1M3.8%+799,999NewHistory
UTHRUnited Therapeutics CorpCOM86,667$16.0M3.8%−89,739−50.9%ReducedHistory
VRTXVertex Pharmaceuticals IncStock85,000$15.4M3.6%+85,000NewHistory
TVTXTravere Therapeutics, Inc.COM625,000$15.2M3.6%−459,300−42.4%ReducedHistory
ANABAnaptysbio, IncCOM549,545$14.9M3.5%+149,494+37.4%AddedHistory
CYTKCytokinetics IncCOM NEW391,429$14.0M3.3%+391,429NewHistory
BIIBBiogen Inc.COM47,500$13.4M3.2%+15,000+46.2%AddedHistory
URGNUroGen Pharma Ltd.COM750,000$12.6M3.0%+750,000NewHistory
DYNDyne Therapeutics, Inc.COM745,000$12.1M2.9%+72,441+10.8%AddedHistory
SAGESage Therapeutics, Inc.COM269,010$11.9M2.8%+19,010+7.6%AddedHistory
XENEXenon Pharmaceuticals Inc.COM700,000$10.7M2.5%+700,000NewHistory
TCDATricida, Inc.COM1,974,000$9.16M2.2%00.0%UnchangedHistory
PBYIPuma Biotechnology, Inc.COM1,300,000$9.11M2.2%00.0%UnchangedHistory
OLMAOlema Pharmaceuticals, Inc.COM329,086$9.07M2.1%00.0%UnchangedHistory
NKTRNektar TherapeuticsCOM504,691$9.06M2.1%+504,691NewHistory
ACRSAclaris Therapeutics, Inc.COM500,000$9.00M2.1%+500,000NewHistory
RFLRafael Holdings, Inc.COM CL B285,714$8.78M2.1%+285,714NewHistory
DNTHDianthus Therapeutics, Inc.COM1,170,000$8.52M2.0%+58,889+5.3%AddedHistory
CTMXCytomX Therapeutics, Inc.COM1,500,000$7.63M1.8%+500,000+50.0%AddedHistory
RIGLRigel Pharmaceuticals IncCOM NEW1,980,000$7.19M1.7%+480,000+32.0%AddedHistory
SYRESpyre Therapeutics, Inc.COM900,000$7.16M1.7%00.0%UnchangedHistory
PHATPhathom Pharmaceuticals, Inc.COM220,863$7.09M1.7%+220,863NewHistory
KNSAKiniksa Pharmaceuticals International, plcCOM CL A480,000$5.47M1.3%+480,000NewHistory
PCVXVaxcyte, Inc.COM98,061$2.49M0.6%+98,061NewHistory
RPTXRepare Therapeutics Inc.COM93,137$2.44M0.6%−342,952−78.6%ReducedHistory
COLLCollegium Pharmaceutical, IncCOM121,342$2.40M0.6%−740,068−85.9%ReducedHistory
FOLDAmicus Therapeutics, Inc.COM249,000$2.38M0.6%−1,351,000−84.4%ReducedHistory
IFRXInflaRx N.V.COM551,918$1.43M0.3%−1,648,082−74.9%ReducedHistory
PRQRProQR Therapeutics N.V.SHS EURO30,336$254.0K0.1%+30,336NewHistory

Options (1)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Great Point Partners LLC in Q3 2021
SecurityClassPutsCalls
APLSApellis Pharmaceuticals, Inc.COM–$6.59M

Sold out since Q2 2021 (6)

Positions held at the end of Q2 2021 that are gone from this filing.

Positions of Great Point Partners LLC sold out since Q2 2021
SecurityClassShares in Q2 2021Value in Q2 2021% of portfolio in Q2 2021History
PODDInsulet CorpStock104,600$28.7M6.4%History
MRTXMirati Therapeutics, Inc.COM100,000$16.2M3.6%History
OCULOcular Therapeutix, IncCOM919,887$13.0M2.9%History
XENTIntersect ENT, Inc.COM700,000$12.0M2.7%History
KURAKura Oncology, Inc.COM500,000$10.4M2.3%History
VERVVerve Therapeutics, Inc.COM35,000$2.11M0.5%History